114 related articles for article (PubMed ID: 32667286)
1. Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects.
Reyes M; Lutz JD; Lau AH; Gaggar A; Grant EP; Joshi A; Mackman RL; Ling J; Tan SK; Ayithan N; Daffis S; Woo J; Wu P; Lam T; Fletcher SP; Kottilil S; Poonia B; Gane EJ; Mathias A; German P
Antivir Ther; 2020; 25(3):171-180. PubMed ID: 32667286
[TBL] [Abstract][Full Text] [Related]
2. Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B.
Gane EJ; Kim HJ; Visvanathan K; Kim YJ; Nguyen AH; Wallin JJ; Chen DY; McDonald C; Arora P; Tan SK; Gaggar A; Roberts SK; Lim YS
Hepatology; 2021 Oct; 74(4):1737-1749. PubMed ID: 33704806
[TBL] [Abstract][Full Text] [Related]
3. Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.
Mackman RL; Mish M; Chin G; Perry JK; Appleby T; Aktoudianakis V; Metobo S; Pyun P; Niu C; Daffis S; Yu H; Zheng J; Villasenor AG; Zablocki J; Chamberlain J; Jin H; Lee G; Suekawa-Pirrone K; Santos R; Delaney WE; Fletcher SP
J Med Chem; 2020 Sep; 63(18):10188-10203. PubMed ID: 32407112
[TBL] [Abstract][Full Text] [Related]
4. Oral Selective TLR8 Agonist Selgantolimod Induces Multiple Immune Cell Responses in Humans.
Ayithan N; Ghosh A; Dwivedi A; Wallin JJ; Tan SK; Chen D; Kottilil S; Poonia B
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960669
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression.
Gane EJ; Dunbar PR; Brooks AE; Zhang F; Chen D; Wallin JJ; van Buuren N; Arora P; Fletcher SP; Tan SK; Yang JC; Gaggar A; Kottilil S; Tang L
J Hepatol; 2023 Mar; 78(3):513-523. PubMed ID: 38133554
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.
Amin OE; Colbeck EJ; Daffis S; Khan S; Ramakrishnan D; Pattabiraman D; Chu R; Micolochick Steuer H; Lehar S; Peiser L; Palazzo A; Frey C; Davies J; Javanbakht H; Rosenberg WMC; Fletcher SP; Maini MK; Pallett LJ
Hepatology; 2021 Jul; 74(1):55-71. PubMed ID: 33368377
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection.
Janssen HL; Lim YS; Kim HJ; Sowah L; Tseng CH; Coffin CS; Elkhashab M; Ahn SH; Nguyen AH; Chen D; Wallin JJ; Fletcher SP; McDonald C; Yang JC; Gaggar A; Brainard DM; Fung S; Kim YJ; Kao JH; Chuang WL; Brooks AE; Dunbar PR
JHEP Rep; 2024 Feb; 6(2):100975. PubMed ID: 38274492
[TBL] [Abstract][Full Text] [Related]
8. Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B.
Daffis S; Balsitis S; Chamberlain J; Zheng J; Santos R; Rowe W; Ramakrishnan D; Pattabiraman D; Spurlock S; Chu R; Kang D; Mish M; Ramirez R; Li L; Li B; Ma S; Hung M; Voitenleitner C; Yon C; Suresh M; Menne S; Cote P; Delaney WE; Mackman R; Fletcher SP
Hepatology; 2021 Jan; 73(1):53-67. PubMed ID: 32246499
[TBL] [Abstract][Full Text] [Related]
9. Follicular Helper T (T
Ayithan N; Tang L; Tan SK; Chen D; Wallin JJ; Fletcher SP; Kottilil S; Poonia B
Front Immunol; 2021; 12():735913. PubMed ID: 34512670
[TBL] [Abstract][Full Text] [Related]
10. A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers.
Luk A; Jiang Q; Glavini K; Triyatni M; Zhao N; Racek T; Zhu Y; Grippo JF
Clin Transl Sci; 2020 Sep; 13(5):985-993. PubMed ID: 32268000
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals.
Hu Y; Zhang H; Wu M; Liu J; Li X; Zhu X; Li C; Chen H; Liu C; Niu J; Ding Y
Expert Opin Investig Drugs; 2021 Mar; 30(3):263-269. PubMed ID: 33405993
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist.
Lopatin U; Wolfgang G; Tumas D; Frey CR; Ohmstede C; Hesselgesser J; Kearney B; Moorehead L; Subramanian GM; McHutchison JG
Antivir Ther; 2013; 18(3):409-18. PubMed ID: 23416308
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers.
Grippo JF; Folitar I; Passe S; Jiang Q; Rodriguez I; Fettner SH; Calleja E
Clin Transl Sci; 2021 Jul; 14(4):1524-1534. PubMed ID: 33742764
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.
Janssen HLA; Brunetto MR; Kim YJ; Ferrari C; Massetto B; Nguyen AH; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Yoshida EM; Ahn SH; Tsai NCS; Fung S; Gane EJ
J Hepatol; 2018 Mar; 68(3):431-440. PubMed ID: 29104121
[TBL] [Abstract][Full Text] [Related]
16. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8.
Port A; Shaw JV; Klopp-Schulze L; Bytyqi A; Vetter C; Hussey E; Mammasse N; Ona V; Bachmann A; Strugala D; Reh C; Goteti K
Pharmacol Res Perspect; 2021 Oct; 9(5):e00842. PubMed ID: 34414672
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
[TBL] [Abstract][Full Text] [Related]
19. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.
Gane EJ; Lim YS; Gordon SC; Visvanathan K; Sicard E; Fedorak RN; Roberts S; Massetto B; Ye Z; Pflanz S; Garrison KL; Gaggar A; Mani Subramanian G; McHutchison JG; Kottilil S; Freilich B; Coffin CS; Cheng W; Kim YJ
J Hepatol; 2015 Aug; 63(2):320-8. PubMed ID: 25733157
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modelling of the novel H
Venail F; Attali P; Wersinger E; Gomeni R; Poli S; Schmerber S
Br J Clin Pharmacol; 2018 Dec; 84(12):2836-2848. PubMed ID: 30152527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
